GlaxoSmithKline News and Research

RSS

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.

24 Jul 2014

Isis earns $1 million payment from GSK related to advancement of ISIS-TTRRx

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

16 Jul 2014

Scientists release recommendations for evaluating pharmacological safety of oligonucleotide therapeutics

Novel oligonucleotide-based drugs in development offer promising alternatives for treating a range of diseases.

8 Jul 2014

Study analyzes effects of antidepressant drugs on well-being in children and adolescents

In an article published in the current issue of Psychotherapy and Psychosomatics the effects of antidepressant drugs on well-being in children and adolescents are analyze.

7 Jul 2014

Isis Pharmaceuticals gets $1 million from GSK to discover and develop drugs for HBV

Isis Pharmaceuticals, Inc. announced today that it has earned a $1 million payment from GlaxoSmithKline related to the advancement of its program to develop antisense drugs to treat hepatitis B virus (HBV).

2 Jul 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

Generic drug delays cost U.S. payers millions

Problems surrounding an Indian company's launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal.

19 Jun 2014

First Edition: June 18, 2014

Today's headlines include a report that the cost of health law subsidies may push the measure's overall price tag beyond projections.

18 Jun 2014

New study show direct link between depression and medication nonadherence

A new study led by Alan B. Ettinger, M.D., M.B.A., Director of the Epilepsy Center at Neurological Surgery, P.C., has found that many patients who fail to take their antiseizure medications are suffering from depression.

12 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

Research report on sports nutrition market in Europe

Sports Nutrition Market in Europe 2014-2018 has been prepared based on an in-depth market analysis with inputs from industry experts.

31 May 2014

Novozymes Biopharma to assess novel subunit vaccine candidate using Veltis technology

Novozymes Biopharma has entered a new collaborative research agreement with one of the world’s top vaccine companies. The partnership will enable the company to evaluate Novozymes Biopharma's modified recombinant human albumin (rAlbumin) Veltis technology, to assess the dosing and performance of a novel subunit antigen vaccine candidate.

30 May 2014

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan Inc. today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets.

29 May 2014

UK opens criminal inquiry into Glaxosmithkline business practices

The British drug maker GlaxoSmithKline said late Tuesday that the Serious Fraud Office of Britain had opened a formal criminal investigation into its "commercial practices." Neither GlaxoSmithKline nor the fraud office provided further details about what practices were being investigated. .

29 May 2014

First Edition: May 28, 2014

Today's early morning highlights from the major news organizations, including reports about efforts to cut back spending on cancer care and the ouster of a key Army hospital administrator.

28 May 2014

Half-life extension technology: an interview with Dermot Pearson, Novozymes Biopharma

A drug's half-life indicates how long a substance will remain active in the body. It is essentially the period of time that it takes for the concentration of the amount of the drug to be reduced by half, and therefore, determines how frequently a drug needs to be administered to maintain its therapeutic effect.

27 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014